CN111388510A - Probiotic composition - Google Patents
Probiotic composition Download PDFInfo
- Publication number
- CN111388510A CN111388510A CN202010338579.8A CN202010338579A CN111388510A CN 111388510 A CN111388510 A CN 111388510A CN 202010338579 A CN202010338579 A CN 202010338579A CN 111388510 A CN111388510 A CN 111388510A
- Authority
- CN
- China
- Prior art keywords
- fruit powder
- probiotic composition
- lactobacillus acidophilus
- bifidobacterium lactis
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 32
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 32
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 29
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 17
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 17
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 17
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 15
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims abstract description 9
- 240000003394 Malpighia glabra Species 0.000 claims abstract description 9
- 235000014837 Malpighia glabra Nutrition 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920001353 Dextrin Polymers 0.000 claims abstract description 6
- 239000004375 Dextrin Substances 0.000 claims abstract description 6
- 229920001202 Inulin Polymers 0.000 claims abstract description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 6
- 235000019425 dextrin Nutrition 0.000 claims abstract description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 6
- 229940029339 inulin Drugs 0.000 claims abstract description 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 6
- 229940045731 elderberry fruit Drugs 0.000 claims abstract description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 3
- 235000015165 citric acid Nutrition 0.000 claims abstract description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 3
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 3
- 239000000600 sorbitol Substances 0.000 claims abstract description 3
- 229960002920 sorbitol Drugs 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 13
- 239000013566 allergen Substances 0.000 abstract description 9
- 241000167854 Bourreria succulenta Species 0.000 abstract description 8
- 235000019693 cherries Nutrition 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 229940088592 immunologic factor Drugs 0.000 abstract description 3
- 239000000367 immunologic factor Substances 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 241000208829 Sambucus Species 0.000 description 4
- 235000018735 Sambucus canadensis Nutrition 0.000 description 4
- 235000007123 blue elder Nutrition 0.000 description 4
- 235000007124 elderberry Nutrition 0.000 description 4
- 235000008995 european elder Nutrition 0.000 description 4
- 235000021028 berry Nutrition 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The invention discloses a probiotic composition, which comprises lactobacillus acidophilus, bifidobacterium lactis, sorbitol, natural fruit powder, prebiotics, citric acid and silicon dioxide; wherein the natural fruit powder comprises elderberry fruit powder and acerola cherry fruit powder; prebiotics include inulin, resistant dextrins and stachyose. The probiotic composition provided by the invention effectively reduces over-stimulated immune factors, reduces the dosage of external dermatitis drugs, simultaneously promotes children digestion, is matched with natural fruit powder (elderberry fruit powder and acerola cherry powder) for promoting immune health, does not use an embedding technology, does not add suspected allergens such as essence and pigment, and can effectively avoid over-stimulated immunity, regulate intestinal flora of children, and promote metabolism and discharge of the allergens.
Description
Technical Field
The invention relates to a probiotic composition, and in particular relates to a probiotic composition for improving allergic dermatitis.
Background
Allergy in children has endogenous and exogenous causes, endogenous is mainly a part of immune proteins in children higher than normal values, and immune balance is unbalanced Th1/Th2, and exogenous is generally caused by some exogenous nutrients also called allergen. The specific probiotic combination can reduce overhigh immune factors and reduce immune overstimulation on the one hand; on the other hand, the intestinal flora of children can be adjusted, and the metabolism and the discharge of the allergen are promoted.
Most of the existing probiotic compositions are single-bacterium researches, few human clinical researches of formula combination exist, many researches focus on single exogenous or endogenous improvement, and the single exogenous or endogenous improvement cannot be achieved at the same time.
Disclosure of Invention
The present invention aims to provide a probiotic composition to solve the problems set forth in the background art.
In order to achieve the purpose, the invention provides the following technical scheme:
a probiotic composition comprising lactobacillus acidophilus, bifidobacterium lactis, sorbitol, natural fruit powder, prebiotics, citric acid and silicon dioxide.
Preferably, the probiotic composition comprises the following components in percentage by mass:
preferably, the natural fruit powder comprises 3-5% of elderberry fruit powder and 3-5% of acerola cherry fruit powder.
Preferably, the prebiotics comprise 20-25% of inulin, 15-20% of resistant dextrin and 1-5% of stachyose.
Preferably, the activity of the combination of lactobacillus acidophilus and bifidobacterium lactis is 80 to 150 hundred million CFU/g.
Preferably, the lactobacillus acidophilus strain number is lactobacillus acidophilus DDS-1, and the bifidobacterium lactis strain number is bifidobacterium lactis UABla-12.
The lactobacillus acidophilus and the bifidobacterium lactis are two common probiotics, one of the two probiotics acts on the small intestine and the other acts on the large intestine, the two probiotics are matched to be more adhered to the surface of the intestinal tract, the adhesion effect is better than that of the single lactobacillus or bifidobacterium, and meanwhile, the adhesion effect of the probiotics can activate the normal immune response of the intestinal tract and reduce the overstimulation response of the intestinal tract to the allergen;
the elderberry and the acerola cherry are traditional European berries, have auxiliary improvement effects on cold, fever, dermatitis and the like after being used for a long time in folk, are natural vitamin C sources, and have a good effect of enhancing the immunity.
The probiotic composition provided by the invention effectively reduces over-stimulated immune factors, reduces the dosage of external dermatitis drugs, simultaneously promotes children digestion, is matched with natural fruit powder (elderberry fruit powder and acerola cherry powder) for promoting immune health, does not use an embedding technology, does not add essence, pigment and the like, can be used as an allergen, can effectively avoid over-stimulation of immunity, regulates intestinal flora of children, and promotes metabolism and discharge of the allergen.
Detailed Description
The present invention will be further described with reference to the following examples.
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The conditions in the embodiments can be further adjusted according to specific conditions, and simple modifications of the method of the present invention based on the concept of the present invention are within the scope of the claimed invention.
Example 1
The probiotic composition comprises the following components in percentage by mass:
wherein the activity of the combination of Lactobacillus acidophilus and Bifidobacterium lactis is 100 hundred million CFU/g.
In this example, prebiotics: the total ratio of inulin, resistant dextrin and stachyose is 45%, and the ratio of natural fruit powder: the total ratio of elderberry powder to acerola cherry powder is 10%, and the probiotics regulates intestinal flora and the natural fruit powder are beneficial to improving the immune response of the intestinal tract, enhancing the immune function of the intestinal tract, promoting the immune balance and reducing inflammation.
Example 2
The probiotic composition comprises the following components in percentage by mass:
wherein the activity of the combination of Lactobacillus acidophilus and Bifidobacterium lactis is 150 hundred million CFU/g.
In this example, prebiotics: the total ratio of inulin, resistant dextrin and stachyose is 55%, and the natural fruit powder: the total ratio of elderberry powder to acerola cherry powder is 6%, and the contents of probiotics with higher activity and more prebiotics are adopted to promote the intestinal tract movement and peristalsis more quickly and accelerate the discharge of allergen.
Example 3
The probiotic composition comprises the following components in percentage by mass:
wherein the activity of the combination of Lactobacillus acidophilus and Bifidobacterium lactis is 125 hundred million CFU/g.
In this example, prebiotics: the total ratio of inulin, resistant dextrin and stachyose is 50%, and the ratio of natural fruit powder: the total proportion of the elderberry powder and the acerola cherry powder is 8%, the embodiment gives consideration to the activity of probiotics, the content of prebiotics and the proportion of natural fruit powder are balanced, and the intestinal tract operation is promoted while the immune health is balanced.
In conclusion, the probiotic composition can effectively adhere to intestinal epithelial cells, produce bioactive agents such as bacteriocins and the like, and reduce adhesion of pathogenic bacteria or allergens.
The probiotic composition controls the ratio of the berries to be within 10% by adjusting the ratio, and the berries containing high effective components are selected to reduce the addition amount influencing the water activity of the finished product and ensure the health benefit;
the formula selects three prebiotics, wherein the prebiotics are taken as food of probiotics in intestinal tracts, and the matching of diversified prebiotics is more beneficial to the colonization of different probiotics in the intestinal tracts and has better value-added effect than that of single prebiotics.
The lactobacillus acidophilus and the bifidobacterium lactis in the formula have good tolerance in gastric acid, so that an embedding technology is not needed, and the stability of the combined product in the shelf life is facilitated.
The tolerance levels for lactobacillus acidophilus and bifidobacterium lactis are shown in the following table:
in the above table, "+" is used to indicate the tolerance level, the higher the number of "+" is, the higher the survival rate of lactobacillus acidophilus and bifidobacterium lactis is:
for bile:
"+" tolerance (overnight, less than 60% survival);
"+ + +" resistant (overnight, 60% -69% survival);
"+ ++" high resistance (overnight, 70-79% survival);
"++++" is very resistant (overnight, 80% -89% survival);
"+ +++" is ultra-high resistant (overnight, over 90% survival).
For gastric acid:
"+" tolerance (less than 59% survival after 2 hours);
"+ + +" resistant (60% -69% survival after 2 hours);
"+ + + +" high resistance (70-79% survival after 2 hours);
"+ +++" is very resistant (80% -89% survival after 2 hours);
"+ +++" is ultra-high resistant (over 90% survival after 2 hours).
In summary, the combination of lactobacillus acidophilus and bifidobacterium lactis was still 90% in stock after 2 hours in gastric acid. Therefore, embedding is not required.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. A probiotic composition, characterized in that it comprises lactobacillus acidophilus, bifidobacterium lactis, sorbitol, natural fruit powder, prebiotics, citric acid and silicon dioxide.
2. The probiotic composition according to claim 1, characterized in that it comprises the following components in mass percent:
3. the probiotic composition according to claim 2, characterized in that the natural fruit powder comprises 3% to 5% elderberry fruit powder and 3% to 5% acerola fruit powder.
4. The probiotic composition according to claim 2, characterized in that the prebiotic comprises 20 to 25% inulin, 15 to 20% resistant dextrin and 1 to 5% stachyose.
5. The probiotic composition according to claim 2, characterized in that the combined activity of said lactobacillus acidophilus and said bifidobacterium lactis is comprised between 80 and 150 hundred million CFU/g.
6. The probiotic composition according to claim 2, characterized in that the lactobacillus acidophilus strain number is lactobacillus acidophilus DDS-1 and the bifidobacterium lactis strain number is bifidobacterium lactis UABla-12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010338579.8A CN111388510A (en) | 2020-04-26 | 2020-04-26 | Probiotic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010338579.8A CN111388510A (en) | 2020-04-26 | 2020-04-26 | Probiotic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111388510A true CN111388510A (en) | 2020-07-10 |
Family
ID=71417200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010338579.8A Withdrawn CN111388510A (en) | 2020-04-26 | 2020-04-26 | Probiotic composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111388510A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111869733A (en) * | 2020-07-31 | 2020-11-03 | 贝因美股份有限公司 | Hypoallergenic lactoprotein functional factor composition, application thereof and hypoallergenic child formula milk powder |
| CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
| CN112056481A (en) * | 2020-09-30 | 2020-12-11 | 上海恒腾生物科技有限公司 | Formula and preparation method of active probiotic solid beverage |
| CN112514994A (en) * | 2020-12-17 | 2021-03-19 | 海而思（郑州）科技有限公司 | Probiotic combined solid beverage and preparation method thereof |
-
2020
- 2020-04-26 CN CN202010338579.8A patent/CN111388510A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111869733A (en) * | 2020-07-31 | 2020-11-03 | 贝因美股份有限公司 | Hypoallergenic lactoprotein functional factor composition, application thereof and hypoallergenic child formula milk powder |
| CN111990461A (en) * | 2020-08-18 | 2020-11-27 | 北安宜品努卡乳业有限公司 | Mixed milk powder for enhancing immunity and preparation method thereof |
| CN112056481A (en) * | 2020-09-30 | 2020-12-11 | 上海恒腾生物科技有限公司 | Formula and preparation method of active probiotic solid beverage |
| CN112514994A (en) * | 2020-12-17 | 2021-03-19 | 海而思（郑州）科技有限公司 | Probiotic combined solid beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388510A (en) | Probiotic composition | |
| AU2003298411B2 (en) | Composition comprising lactobacilli or bifidobacteria and use thereof | |
| Lillo-Pérez et al. | Probiotics in fruit and vegetable matrices: Opportunities for nondairy consumers | |
| US7740838B2 (en) | Bacterial composition and its use | |
| Chandan | Enhancing market value of milk by adding cultures | |
| TWI633846B (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| US20120135044A1 (en) | Instant thickener comprising probiotics for hot or cold foods and beverages to be administered to dysphagic patients | |
| CN107594279A (en) | A kind of probiotic powder solid beverage and preparation method thereof | |
| AU2004241895B2 (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property | |
| CN108142770A (en) | A kind of polynary probiotics solid beverage of breast peptide | |
| CN112869170B (en) | Probiotics prebiotic nutritional composition capable of improving gastrointestinal tract immunity and application | |
| MX2011006488A (en) | Compositions and methods for improved oral health. | |
| CN112375727B (en) | Application of lactoferrin in promoting proliferation of bifidobacteria and lactobacilli | |
| CN108771072A (en) | A kind of probiotic composition and infant's probiotics solid beverage | |
| Ortiz et al. | Functional dairy products | |
| CN112056481A (en) | Formula and preparation method of active probiotic solid beverage | |
| CN111374256A (en) | Probiotic composition, use thereof, food and medicament | |
| Lalles | Nutrition and gut health of the young pig around weaning: what news? | |
| CN107647410A (en) | A kind of probiotic powder of compound proportioning and preparation method thereof | |
| Suda et al. | Soymilk-fermented with Lactobacillus delbrueckii subsp. delbrueckii TUA4408L improves immune-health in pigs | |
| EP3313206A1 (en) | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children | |
| CN113712207B (en) | Probiotic prebiotic composition for improving gastrointestinal tract immunity and application thereof | |
| EP1911455B1 (en) | Topical vaginal pharmaceutical compositions | |
| CN113678978A (en) | Dietary fiber probiotic solid beverage | |
| CN112868803A (en) | Formula milk powder for improving breast milk nutrition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200710 |
|
| WW01 | Invention patent application withdrawn after publication |